Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 5, 1997, Pages 518-526

  Bruno, René ^a   Vivier, Nicole ^b   Montay, Guy ^b   Le Liboux, Aimé ^b   Powe, Larry K ^b   Delumeau, Jean Christophe ^b   Rhodes, Gerald R ^b  

^a Drug Metabolism and Pharmacokinetics   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION DYNAMICS; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; STATISTICS;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RILUZOLE;

EID: 0031421232     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90047-3     Document Type: Article

References (17)

1. Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984;15:153-71.
2. Sheiner LB, Benet LZ. Premarketing observational studies of population pharmacokinetics of new drugs. Clin Pharmacol Ther 1985;38:481-7.
3. Grasela TH, Antal EJ, Townsend RJ, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials; part I: comparison of methodologies. Clin Pharmacol Ther 1986;39:605-12.
4. Antal EJ, Grasela TH, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials; part III: prospective data collection versus retrospective data assembly. Clin Pharmacol Ther 1989;46: 552-9.
5. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 1972;5:441-59.
6. Ludden TM. Population pharmacokinetics. J Clin Pharmacol 1988;28:1059-63.
7. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 1992;51:465-73.
8. Temple R. The clinical investigation of drugs for use by the elderly: food and drug guidelines. Clin Pharmacol Ther 1987;42:681-5.
9. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V for the Amyotrophic Lateral Sclerosis/ Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347:1425-31.
10. Beal SL, Sheiner LB. The NONMEM system. Am Statist 1980;34:118-9.
11. Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm 1991;19:333-53.
12. Le Liboux A, Lefebvre P, Le Roux Y, Truffinet P, Aubeneau M, Kirkesseli S, et al. Single- and multiple-dose pharmacokinetics of riluzole in Caucasian subjects. J Clin Pharmacol [in press].
13. Beal SL, Boeckman AJ, Sheiner LB. NONMEM user's guide, parts I-VII. San Francisco: University of California at San Francisco; 1988-1992.
14. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993;21:735-50.
15. SAS/STAT. Changes and enhancements through release 6.11. Gary, NC: SAS Institute; 1996.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16: 31-41.
17. Sanderink GJ, Bournique B, Stevens J, Petry M, Martinet M. Involvement of human CYP1A isoenzymes in the hepatic metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther [in press].